TMEM41A and neoplasm: Similarly, TMEM41A overexpression was associated with shorter DSS in patients with EC with stages I, I-II, I-III, II-III, II-IV, and III, weight ≤ 80 or > 80kg, height, BMI, G2-3 grade, endometrioid, tumor invasion, age > 60 years, hormone therapy (no), radiotherapy (no), diabetes (yes or no) (Fig 4).